Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623371 | 0.83 | BACE1 (0.33) | — | |
| SCHEMBL23015668 | 0.81 | IRAK4 (0.34) | — | |
| SCHEMBL18559674 | 0.81 | NOS3 (0.36) | ESR1 | |
| SCHEMBL15071168 | 0.79 | NOS1 (0.33) | — | |
| SCHEMBL830961 | 0.78 | NOS3 (0.36) | — | |
| SCHEMBL1106488 | 0.78 | NOS3 (0.36) | — | |
| SCHEMBL24224418 | 0.78 | NOS3 (0.40) | ESR1 | |
| SCHEMBL19602407 | 0.78 | — | — | |
| SCHEMBL23015852 | 0.78 | CYP2A6 (0.30) | — | |
| SCHEMBL23015746 | 0.76 | KCNH2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-31 | — | — | US | disclosed |
| US-11730810-B2 | Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11673891-B2 | Imidazopyrimidine compounds and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11638705-B2 | 4(1H)-quinolone derivatives and uses thereof | ACADEMIA SINICA (TW) | 2023-05-02 | — | — | US | disclosed |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-10039816-B2 | Siderophore-based immunization against gram-negative bacteria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180030213-A1 | BLOCK CO-POLY(METAL ORGANIC NANOSTRUCTURES) (BCPMONS) AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2014093723-A2 | GROUP-ASSISTANT-PURIFICATION (GAP) SYNTHESIS OF VELCADE, DIMERIC ANALOGS, AND AMINO COMPOUNDS | NANJING UNIVERSITY (CN) | 2014-06-19 | — | — | WO | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638705-B2 | 4(1H)-quinolone derivatives and uses thereof | TUBB1, TUBB3, TUBB | ESR1 2984/4885 |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | ESR1 4583/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | ESR1 884/4885 |
| US-20150344457-A1 | METHODS OF INHIBITING PRMT5 | PRMT5, PRMT1, PRMT7 | ESR1 4375/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ESR1 941/4885 |
| US-11730810-B2 | Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response | CD4, MYD88, STING1 | ESR1 3296/4885 |
| US-20180030213-A1 | BLOCK CO-POLY(METAL ORGANIC NANOSTRUCTURES) (BCPMONS) AND USES THEREOF | MB, EBPL, POF1B | ESR1 2963/4885 |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | SIK1, SIK2, SIK3 | ESR1 4688/4885 |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | ESR1 3840/4885 |
| US-20230271950-A1 | ANTIBACTERIAL PICOLINAMIDE COMPOUNDS | RPL35, RPL5, RPL23 | ESR1 4653/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | ESR1 2212/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | ESR1 1242/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | ESR1 600/4885 |
| US-10039816-B2 | Siderophore-based immunization against gram-negative bacteria | SLC40A1, SFXN1, SLC75A1 | ESR1 3632/4885 |
| US-11673891-B2 | Imidazopyrimidine compounds and uses thereof | HLA-DRB1, HLA-A, IRF3 | ESR1 4447/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | ESR1 4213/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | ESR1 3605/4885 |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | ESR1 4688/4885 |
| US-20230346942-A1 | MACROMOLECULAR PRODRUGS FOR LIGHT-EMITTING DIODES AND USES THEREOF | CRY1, MAPT, PYGL | ESR1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.